Search Results

VA provides best in class care for Veterans facing prostate cancer. 

VA is at the forefront of prostate cancer care and innovation.

VA can support you through a diagnosis of prostate cancer with access to the latest technology and approaches for individualized care.

As part of a new research study that began July [...]

While active surveillance sounds like a logical approach for men with low-risk prostate cancer, especially given that prostate removal and radiotherapy can lead to urinary, bowel, and sexual dysfunction, convincing patients to buy into it can be a challenge all its own.

After Marine Corps Veteran Joe Gallo was diagnosed with prostate cancer, he and two others created a virtual support group for prostate cancer patients.

Images from a positron emission tomography (PET) scanner show the location of the cancer. This type of drug appears to be the best diagnostic tool for staging prostate cancer and determining whether it has metastasized, says Dresser, the chief of nuclear medicine at the Truman VA.

I’m involved in prostate cancer basic research and new drug development. Prostate cancer is the most common non-skin cancer in Veterans. About 35,000 Veterans with prostate cancer receive treatment in the VA system.

Prostate cancer is the most commonly diagnosed cancer among Veterans in VA. It accounts for nearly a third of cancer diagnoses. Prostate cancer is often found early and cured with treatments such as surgery or radiation. But some patients’ cancer spreads and becomes life-threatening.

Genetic testing looks for variations in a person’s genes. Finding gene variations can help with decisions about cancer treatment. Finding gene variations can also help to understand why cancer developed and how best to find cancers early or to prevent them altogether.

The researchers conducted a systematic review of 67 studies to compare the effectiveness of watchful waiting versus radical prostatectomy, along with several other treatments. The review is one of the first studies to look at very long-term results.

Today at age 56, Atkinson is fighting another battle—this time a case of aggressive prostate cancer. Thanks to treatment at the VA Portland Health Care System, his condition has improved dramatically in recent months through precision oncology—the molecular profiling of tumors to identify targetable alterations that can be treated therapeutically. Most recently, his PSA level had plummeted to 0.2, after a high of 115 in December.